passages: 3625
passages: document
passages: Changes in the fatty acid composition of the plasma lipid esters during lipid-lowering treatment with diet , clofibrate and niceritrol . Reduction of the proportion of linoleate by clofibrate but not by niceritrol . The fatty acid composition of the plasma lipid esters has been studied during lipid-lowering treatment of 95 patients with atherosclerotic disease . During the first two months of the trial only a diet was prescribed . During the ensuing two months either clofibrate or niceritrol , a nicotinic acid ester , was added in a randomized order . During the last two months the second drug was added . The combined treatment with diet , clofibrate and niceritrol caused highly significant serum lipid reductions . The fatty acid composition in the plasma lipid esters was determined in samples from each trial period to measure the degree of dietary adherence . During dietary treatment the relative content of saturated and monounsaturated fatty acids secreased and the polyunsaturated fatty acids increased with an increasing ratio between pulyunsaturated and saturated fatty acids ( P/S ratio ) in the cholesterol esters and triglycerides . Only minor changes were seen in the phospholipids . The changes caused by the diet were partly reversed by clofibrate while niceritrol did not cause any major changes of the fatty acid composition . Clofibrate treatment coincided with increasing amounts of monounsaturated fatty acids , especially oleate ( 18 : 1 ) , in the cholesterol esters , triglycerides and phospholipids while there were significant reductions of the content of linoleic ( 18 : 2 ) acid in both the cholesterol esters and triglycerides . The 18 : 2/18 : 1 ratio decreased significantly in all the lipid esters analyzed . However , the P/S ratio was not significantly affected , partly because the relative content of saturated fatty acids also tended to decrease during clofibrate treatment . It is concluded that addition of clofibrate treatment to patients who are on a diet enriched with polyunsaturated fats is associated with a change from polyunsaturated to monounsaturated fatty acids in the plasma lipid esters but does not significantly effect the ratio between polyunsaturated and saturated fatty acids . The fatty acid changes caused by clofibrate treatment and counteracted by an increased amount of polyunsaturated fat in the diet .
entities: 3626
entities: Intervention_Pharmacological
entities: diet
entities: 3627
entities: Intervention_Pharmacological
entities: clofibrate
entities: 3628
entities: Intervention_Pharmacological
entities: niceritrol .
entities: 3629
entities: Intervention_Pharmacological
entities: clofibrate
entities: 3630
entities: Intervention_Pharmacological
entities: niceritrol
entities: 3631
entities: Intervention_Pharmacological
entities: diet
entities: 3632
entities: Intervention_Pharmacological
entities: clofibrate
entities: 3633
entities: Intervention_Pharmacological
entities: niceritrol
entities: 3634
entities: Intervention_Pharmacological
entities: diet
entities: 3635
entities: Intervention_Pharmacological
entities: clofibrate
entities: 3636
entities: Intervention_Pharmacological
entities: niceritrol
entities: 3637
entities: Intervention_Pharmacological
entities: Clofibrate
entities: 3638
entities: Intervention_Pharmacological
entities: clofibrate
entities: 3639
entities: Intervention_Pharmacological
entities: diet .
entities: 3640
entities: Outcome_Physical
entities: fatty acid composition of the plasma lipid esters
entities: 3641
entities: Outcome_Physical
entities: linoleate
entities: 3642
entities: Outcome_Physical
entities: fatty acid composition of the plasma lipid esters
entities: 3643
entities: Outcome_Physical
entities: serum lipid
entities: 3644
entities: Outcome_Physical
entities: fatty acid composition in the plasma lipid esters
entities: 3645
entities: Outcome_Physical
entities: content of saturated and monounsaturated fatty acids
entities: 3646
entities: Outcome_Physical
entities: polyunsaturated fatty acids
entities: 3647
entities: Outcome_Physical
entities: ratio between pulyunsaturated and saturated fatty acids ( P/S ratio )
entities: 3648
entities: Outcome_Physical
entities: phospholipids .
entities: 3649
entities: Outcome_Physical
entities: fatty acid composition .
entities: 3650
entities: Outcome_Physical
entities: monounsaturated fatty acids
entities: 3651
entities: Outcome_Physical
entities: oleate
entities: 3652
entities: Outcome_Physical
entities: triglycerides and phospholipids
entities: 3653
entities: Outcome_Physical
entities: content of linoleic ( 18 : 2 ) acid
entities: 3654
entities: Outcome_Physical
entities: P/S ratio
entities: 3655
entities: Outcome_Physical
entities: saturated fatty acids
entities: 3656
entities: Outcome_Physical
entities: polyunsaturated to monounsaturated fatty acids in the plasma lipid esters
entities: 3657
entities: Outcome_Physical
entities: ratio between polyunsaturated and saturated fatty acids .
entities: 3658
entities: Outcome_Physical
entities: acid changes
entities: 3659
entities: Participant_Sample-size
entities: 95 patients with atherosclerotic disease